Hipertensión Arterial de pacientes con covid-19 en el Hospital General Manta
Hipertensión Arterial de pacientes con covid-19
DOI:
https://doi.org/10.37117/s.v19i1.422Keywords:
SARS-CoV-2 , Covid-19, coronavirus, arterial hypertension, antihypertensive treatmentAbstract
The COVID-19 disease is the third outbreak of coronavirus pneumonia, caused by the SARS-CoV-2 coronavirus, so far this century. It most severely affects vulnerable groups, such as the elderly, with immunosuppression and chronic diseases, including high blood pressure, highly relevant in mortality from cardiovascular and cerebrovascular diseases, being a clinical marker of severity of patients with COVID-19 , manifested mainly in ages older than 60 years, and the preventive suspension of the aforementioned antihypertensive treatments can lead to short- to long-term clinical complications.The objective of the study is to determine the prevalence of Arterial Hypertension in patients diagnosed with Covid- 19 at the IESS-Manta Hospital, Ecuador. A retrospective, cross-sectional, descriptive, observational, quantitative approach study was conducted in patients between 20 and 65 years old, who were admitted from March to October 2020 to the second-level Hospital and referral for patients with COVID-19 in the Province. of Manabí-Ecuador. With a population of 905 subjects diagnosed with Covid-19, the controlled variables of age and sex were analyzed. The statistical analysis was based on the descriptive statistics of the AS400 database of the Clinical History of the Health Center. The prevalence of hypertensive patients diagnosed with Covid-19 is 58 for every 100 patients who were admitted for Covid-19 and age between 20 to 65 is equivalent to 84.8%.
Downloads
References
Adhikari, S., Meng, S., Wu, Y., Mao, Y., Ye, R., Wang , Q., et al. (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infectious Diseases of Poverty, 29.
Andersen, K., Rambaut, A., Lipkin, W., Holmes, E., & Garry, R. (2020). The proximal origin of SARS-CoV 2. Nature Medicine, 450-455.Recuperado de: https://www.nature.com/articles/s41591-020-0820-9.pdf
Bernard, S., Rolland, P., Silue, Y., Mailles, A., Campese,. C, Simondon. A., et al. (2019) First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures, January 2020. Euro Surveill, 25 (6). doi: 10.2807/15607917.ES.2020.25.6.2000094.
Bonilla, O. (2020). Para entender la COVID-19. Revista Medicentro Electrónica, 24(3), 595-629. Recuperado de: http://scielo.sld.cu/pdf/mdc/v24n3/1029-3043-mdc-24-03-595.pdf
Bhatraju, P., Ghassemieh, B., Nichols, M., Kim, R., Jerome, K., Nalla, A., et al. (2020). Covid-19 in Critically Ill Patients in the Seattle Region - Case Series. N Engl J Med. doi: 10.1056/NEJMoa2004500.
CDC. National Health Statistics.(2020). Recuperado de: https://www.cdc.gov/media/dpk/diseases-and-conditions/coronavirus/coronavirus-2020.html
CEPAL. (2020). La pandemia del COVID-19 profundiza la crisis de los cuidados en
América Latina y el Caribe. Recuperado de: https://repositorio.cepal.org/bitstream/handle/1136211362/45335/S2000261_es.pdf?sequence=5&isAllowed=y
Chih- Cheng, L., Tzu-Ping, S., Wen-Chien, K., Hung Jen, T., & Po Ren, H. (2020). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges.Recuperado el 16 de 11 de 2020, de International Journal of Antimicrobial Agents.doi.org/10.1016/j.ijantimicag. 2020.105924
Chow, K. Fleming-Dutra, R. Gierke, A. Hall, M.M. Hughes, T. Pilishvili, et al. (2020). Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 -United States. Morb Mortal Wkly Rep., 69. 382-386. doi: 10.15585/mmwr.mm6913e2
Dong , E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID - n real time. Lancet Inf Dis., 533-534.
Guan, W., Ni, Z., Hu., Y., Liang, WH., Ou. CQ., He, JX., et al. (2019).Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. (28)1–13. doi: 10.1056/NEJMoa2002032.
Grasselli, A. Zangrillo, A. Zanella, M. Antonelli, L. Cabrini, A. Castelli, et al. (2020). Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy JAMA. doi: 10.1001/jama.2020.5394
Lighter, M., Phillips, S., Hochman. S., Sterling, D., Johnson, F. Francois, et al. (2020), Obesity Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission Clin. Infect. Dis.
Onder, G. Rezza, G. Brusaferro, S. (2020). Case-fatality rate and characteristics of patients dying in relation to COVID-19 in ItalyJAMA. doi: 10.1001/jama.2020.4683
Organización Mundial de la Salud. (2019). Hipertensión. Recuperado de: https://www.who.int/es/news-room/fact-sheets/detail/hypertension
Organización Mundial de la Salud. (2020).Coronavirus disease 2019 (COVID-19). Situation Report-66.Geneva: WHO. Recuperado de: https://www.who.int/docs/defaultsorce/ coronaviruse/situation-reports/20200326-sitrep-66-covid-19.pdf?sfvrsn=9e5b8b48_2
Sociedad Colombiana de Cardiología & Cirugía Cardiovascular. (2020). Asociación de la Sociedad Colombiana de Cardiología & Cirugía Cardiovascular. Recuperado de: https://scc.org.co/boletin-no-144-principales-mensajes-de-las-guias-de-hipertension-arterial-de-la-ish-en-el-2020/
Shi F, Yu Q, Huang W, Tan C. (2020). Novel Coronavirus (COVID-19) Pneumonia with Hemoptysis as the Initial Symptom: CT and Clinical Features. Korean J Radiol. 1:e42. doi://10.3348/kjr.2020.0181.
Wang, L.S., Wang, Y.R., Ye, D.W., Liu, Q. (2020).A review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J AntimicrobAgents. Recuperado de: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156162/
Wu, Z., & McGoogan. J.M.(2019). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China JAMA., 323,1239-1242. doi: 10.1001/jama.2020.2648
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;(20):1–7 [Epub ahead of print]. doi: 10.1016/S2213-2600(20)30079-5.
Yoon SH, Lee KH, Kim JY, Lee YK, Ko H, Kim KH, et al. (2020).Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea. Korean J Radiol. 21(4):494-500. doi: 10.3348/kjr.2020.0132.
Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy Eur J Allergy Clin Immunol. 1–12. doi: 10.1111/all.14238.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Sinapsis
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
El Copyright posee el propósito de proteger tanto la propiedad intelectual de los autores como sus resultados. El comité editorial de la Revista Sinapsis se compromete con los autores a proteger, defender y preservar tanto su trabajo como su reputación, y toma muy en serio las acusaciones de infracción, plagio, disputas éticas y fraude. Si un autor se da cuenta de un posible plagio, copia de resultados, fraude o infracción, le rogamos que se comunique con la mayor brevedad posible con el comité editorial de la revista Sinapsis.
CC BY-NC-ND: esta licencia permite a los reutilizadores copiar y distribuir el material en cualquier medio o formato solo sin adaptarlo, solo con fines no comerciales y siempre que se le atribuya al creador.
Términos de Licencia:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivada: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
El autor esta en la obligación de seguir las exigencias según lo instruido en la licencia ubicada en el enlace: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
